



1st Announcement and Call for Abstracts

Vaccine Assays

12-13 September 2024

NH Málaga, Málaga, Spain

INTRODUCTION & AIM OF THE WORKSHOP

Immunogenicity assays play a vital role in evaluating the safety and efficacy of vaccines by measuring the immune response induced in vaccinated individuals, and serve as crucial tools in vaccine development, clinical trials, licensure, and post-marketing surveillance.

Various methods are employed in vaccine immunogenicity assays, ranging from traditional techniques like LBAs to advanced technologies such as flow cytometry and multiplex assays, which allow for the simultaneous measurement of multiple immune parameters. Each assay has its advantages and limitations, and the selection of appropriate assays depends on factors such as the vaccine platform, target disease, and desired immune correlates.

Developing assays for (new generation) vaccines can require working with reagents and materials (e.g., cells, pathogens, antigens, assay controls) that are not readily available. Validation of these assays can also be challenging, with limited industry best practice publications and unclear regulatory agency expectations.

In addition to providing feedback from ongoing discussions in the EBF vaccine team, the workshop aims to bring together experts to share experiences, approaches and learnings for establishment and validation of immunogenicity assay which bring added value to the evaluation of safety and efficacy of vaccines.

CALL FOR ABSTRACTS

For this Focus Workshop, we look forward to your contributions, which should fit with the workshop goals:

- Case studies on approaches and types of assays used to characterize vaccine immunogenicity.
- Scientific approaches applied to validation of vaccine immunogenicity assays for different therapeutic modalities.
- Experiences/feedback from regulatory agency on assays used to evaluate vaccine immunogenicity.

You can submit your abstract **before 31-MAY-2024** via <https://meetings.e-b-f.eu/autumnfocus/> (tab: submit an abstract). Inclusion into the program will be evaluated by the organising committee and is based on its fit with the meeting goals. We will communicate acceptance of your abstract before 15-JUN-2024.

MEETING AGENDA & FORMAT

The agenda will include (i) presentations submitted via this call for abstract and (ii) case studies sharing experience from the EBF community. The agenda will become available on the website before the end of June.

The meeting format will be a mix of round table discussions and plenary presentations to optimise the learning and interaction.

For your travel planning, the meeting starts at 09:00 CET on 12-SEP-2024 and ends around 16:00 CET on 13-SEP-2024

WHO SHOULD ATTEND?

Bioanalytical Scientists, experts from Pharma R&D, CRO and academia, and Health Authorities involved in the challenges related to the development, validation and use of vaccine assays.

HOW TO REGISTER

- Registration (registration fee: 580 Euro) opens on 28-FEB-2024. There will be no early bird rate nor 1-day passes.
- For maximum interaction, the meeting attendance is capped to 70 delegates (excluding presenters, for which the registration fee will be waived)
- To register: <https://meetings.e-b-f.eu/autumnfocus/> (tab: Registration).
- The meeting will be at NH, Malaga (Spain). Hotel reservations are independent from the EBF and not included in the meeting registration. More info in travel and lodging: <https://meetings.e-b-f.eu/autumnfocus/> (tab: Travel and Lodging).

MEETING ORGANISATION

Robert Nelson (BioAgilytix), Stefanie Siegert (AC Immune), Arno Kromminga (BioNTech), Salvatore Calogero (Swiss BioQuant) and Philip Timmerman (EBF)